These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32356320)

  • 1. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
    Short NJ; Richard-Carpentier G; Kanagal-Shamanna R; Patel KP; Konopleva M; Papageorgiou I; Pemmaraju N; Borthakur G; Ravandi F; DiNardo CD; Kadia TM; Kantarjian H; Lamba JK; Daver N
    Am J Hematol; 2020 Sep; 95(9):E225-E228. PubMed ID: 32356320
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.
    Oya S; Ozawa H; Morishige S; Maehiro Y; Umeda M; Takaki Y; Fukuyama T; Yamasaki Y; Nakamura T; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
    Int J Hematol; 2024 Sep; 120(3):297-304. PubMed ID: 38963637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
    Rafiee R; Chauhan L; Alonzo TA; Wang YC; Elmasry A; Loken MR; Pollard J; Aplenc R; Raimondi S; Hirsch BA; Bernstein ID; Gamis AS; Meshinchi S; Lamba JK
    Blood Cancer J; 2019 May; 9(6):51. PubMed ID: 31113932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
    Mortland L; Alonzo TA; Walter RB; Gerbing RB; Mitra AK; Pollard JA; Loken MR; Hirsch B; Raimondi S; Franklin J; Pounds S; Cao X; Rubnitz JE; Ribeiro RC; Gamis A; Meshinchi S; Lamba JK
    Clin Cancer Res; 2013 Mar; 19(6):1620-7. PubMed ID: 23444229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
    Lamba JK; Chauhan L; Shin M; Loken MR; Pollard JA; Wang YC; Ries RE; Aplenc R; Hirsch BA; Raimondi SC; Walter RB; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2017 Aug; 35(23):2674-2682. PubMed ID: 28644774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
    Ali S; Dunmore HM; Karres D; Hay JL; Salmonsson T; Gisselbrecht C; Sarac SB; Bjerrum OW; Hovgaard D; Barbachano Y; Nagercoil N; Pignatti F
    Oncologist; 2019 May; 24(5):e171-e179. PubMed ID: 30898889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with
    Teich K; Krzykalla J; Kapp-Schwoerer S; Gaidzik VI; Schlenk RF; Paschka P; Weber D; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Ramachandran D; Benner A; Ganser A; Döhner H; Heuser M; Döhner K; Thol F
    Haematologica; 2021 Nov; 106(11):2986-2989. PubMed ID: 34047179
    [No Abstract]   [Full Text] [Related]  

  • 9. CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.
    Stanchina M; Pastore A; Devlin S; Famulare C; Stein E; Taylor J
    J Hematol Oncol; 2019 Aug; 12(1):85. PubMed ID: 31439003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CLAG±DAC regimen in the treatment of refractory/relapsed acute myeloid leukemia].
    Hua WX; Yao WQ; Zhou M; Qi JQ; Kang HZ; Wang RJ; Cai CS; Liu YJ; Wu DP; Han Y
    Zhonghua Xue Ye Xue Za Zhi; 2024 Sep; 45(9):838-843. PubMed ID: 39414607
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of the combination of decitabine and CHAG priming regimen in the relapsed or refractory acute myeloid leukemia.
    Wu Y; Liang J; Mi R; Wang L; Chen L; Wei X
    Sci Rep; 2024 Nov; 14(1):29161. PubMed ID: 39587191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.
    Gale RE; Popa T; Wright M; Khan N; Freeman SD; Burnett AK; Russell NH; Hills RK; Linch DC
    Blood; 2018 Jan; 131(4):468-471. PubMed ID: 29229596
    [No Abstract]   [Full Text] [Related]  

  • 13. [Efficacy and safety of venetoclax combined with decitabine, modified HA regimen and DLI in the treatment of relapsed pediatric AML/MDS after allogeneic hematopoietic stem cell transplantation].
    Zhang F; Wang HF; Hu GH; Suo P; Bai L; Wang Y; Zhang XH; Huang XJ; Cheng YF
    Zhonghua Xue Ye Xue Za Zhi; 2024 Sep; 45(9):832-837. PubMed ID: 39414606
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
    Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.
    Oya S; Ozawa H; Nakamura T; Mori A; Ochi S; Maehiro Y; Umeda M; Takaki Y; Fukuyama T; Yamasaki Y; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
    Int J Hematol; 2024 Aug; 120(2):194-202. PubMed ID: 38853211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
    Gottardi M; Sperotto A; Ghelli Luserna Di Rorà A; Padella A; Cangini D; Giannini MB; Simonetti G; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):395-410. PubMed ID: 32955828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
    Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
    Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia.
    Hibma J; Knight B
    Clin Pharmacokinet; 2019 Mar; 58(3):335-347. PubMed ID: 30062662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemtuzumab ozogamicin in acute myeloid leukemia.
    Godwin CD; Gale RP; Walter RB
    Leukemia; 2017 Sep; 31(9):1855-1868. PubMed ID: 28607471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.
    Goldfinger M; Mantzaris I; Shastri A; Saunthararajah Y; Gritsman K; Sica RA; Kornblum N; Shah N; Levitz D; Rockwell B; Shapiro LC; Gupta R; Pradhan K; Xue X; Munoz A; Dhawan A; Fehn K; Comas M; Verceles JA; Jonas BA; Kambhampati S; Shi Y; Braunschweig I; Cooper DL; Konopleva M; Feldman EJ; Verma A
    Blood; 2024 Nov; 144(22):2360-2363. PubMed ID: 39316768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.